You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 409 Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
409 Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023210011
Dec 20236708
Jan 20242402
Feb 20244604
Mar 20244205
Apr 20242202
May 202424013
Jun 20245902
Jul 20243002
Aug 20243004
Sep 20245103
Oct 202424012
Nov 20242609
Dec 20243407
Jan 20252404
Feb 2025805
Mar 20250011
Apr 2025002
May 2025107
Jun 2025005
Total7220118